REGULATED INFORMATION
Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results
FDA regulatory submission complete, U.S. approval on track for end of [...] Read more »
REGULATED INFORMATION
Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results
FDA regulatory submission complete, U.S. approval on track for end of [...] Read more »
INFORMATIONS RÉGLEMENTÉES
Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024
Read more »
Nyxoah Publiera ses [...] Read more »
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
Mont–Saint–Guibert, Belgium – July 29, 2024, 10:30pm [...] Read more »
Nyxoah Nomme Scott Holstine Chief Commercial Officer
Mont–Saint–Guibert, Belgique – 15 juillet 2024, 8h00 CET / 2h00 ET – Nyxoah SA (Euronext [...] Read more »
Nyxoah Appoints Scott Holstine as Chief Commercial Officer
Mont–Saint–Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext [...] Read more »
REGULATED INFORMATION
INSIDE INFORMATION
Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment [...] Read more »
INFORMATIONS [...] Read more »
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA
Mont–Saint–Guibert (Belgium), July 1, [...] Read more »
Nyxoah [...] Read more »